Valuation: IDEAYA Biosciences, Inc.

Market Cap 3.77B 3.23B 3.01B 2.77B 5.2B 361B 5.3B 35.75B 13.94B 181B 14.17B 13.86B 599B P/E 2026 *
-8.47x
P/E 2027 * -9.3x
Enterprise Value 2.78B 2.38B 2.22B 2.04B 3.83B 266B 3.91B 26.36B 10.28B 133B 10.44B 10.22B 442B EV / Sales 2026 *
70.7x
EV / Sales 2027 * 23.4x
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.62%
1 week+6.62%
Current month+10.17%
1 month+10.32%
3 months+31.91%
6 months+22.30%
Current year+13.13%
1 week 35.8
Extreme 35.8
39.3
1 month 34.01
Extreme 34.01
39.3
Current year 26.81
Extreme 26.81
40.58
1 year 23.23
Extreme 23.23
40.58
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 2015-05-31
Director of Finance/CFO 51 2025-04-30
Chief Tech/Sci/R&D Officer 59 2022-11-20
Director TitleAgeSince
Chairman 51 2026-06-16
Chairman 67 -
Director/Board Member 71 2015-09-30
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Fiscal year

Controller/Auditor

28,650 0.0327%
6/16/26 Free

Director

20,000 0.0228%
1/30/26 Free

Chief Financial Officer

170,000 0.1940%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%+6.62%+60.81%+48.65% 3.77B
+1.14%+2.27%+2.38%+24.14% 51.22B
-1.36%+4.82%+485.55%+614.84% 45.38B
-2.04%+3.69%+19.34%+91.23% 41.97B
+2.72%+6.02%+33.33%+19.66% 42.15B
0.00%-3.91%+18.49%+47.98% 31.95B
-1.85%+3.48% - - 16.73B
+0.72%+5.27%+31.55%+145.37% 17.1B
+3.06%+3.88%+5.81%+35.00% 14.76B
+0.50%+3.62%+82.64%+46.53% 13.91B
Average +0.35%+3.58%+82.21%+119.27% 27.9B
Weighted average by Cap. +0.22%+3.23%+102.85%+149.35%

Financials

2026 *2027 *
Net sales 39.36M 33.7M 31.44M 28.85M 54.21M 3.77B 55.28M 373M 145M 1.89B 148M 145M 6.25B 115M 98.88M 92.26M 84.66M 159M 11.05B 162M 1.09B 427M 5.54B 434M 424M 18.34B
Net income -432M -370M -345M -317M -595M -41.34B -607M -4.09B -1.6B -20.72B -1.62B -1.59B -68.59B -421M -361M -336M -309M -580M -40.3B -592M -3.99B -1.56B -20.2B -1.58B -1.55B -66.86B
Net Debt -991M -849M -792M -727M -1.37B -94.84B -1.39B -9.39B -3.66B -47.53B -3.72B -3.64B -157B -1.07B -914M -853M -782M -1.47B -102B -1.5B -10.11B -3.94B -51.18B -4.01B -3.92B -169B
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Employees
145
Date Price Change Volume
26-08-20 US$39.11 +0.62% 1,634,020
26-08-19 US$38.87 +2.48% 931,923
26-08-18 US$37.93 +3.80% 629,485
26-08-17 US$36.54 +0.66% 427,842
26-08-14 US$36.30 -1.04% 435,255
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
39.11USD
Average target price
52.15USD
Spread / Average Target
+33.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDYA Stock